Geographic and Racial Disparities in Access to Chimeric Antigen Receptor–T Cells and Bispecific Antibodies Trials for Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.28877
Abstract: Key Points Question Is there equitable geographic access to chimeric antigen receptor–T cells (CAR-T) and bispecific antibodies trials for multiple myeloma in the US? Findings In this cross-sectional study of data from 69 clinical trials… read more here.
Keywords: trials multiple; multiple myeloma; antibodies trials; access chimeric ... See more keywords